Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Fears continue over genetic discrimination:

This article was originally published in Clinica

Executive Summary

The vast majority of cancer genetic counsellors who took part in a US survey on genetic testing said they would undergo such testing if they were at risk of being a cancer gene carrier. However, 68% said they would not bill genetic testing charges to their insurance company and 82% would not want their carrier status documented in their medical records if they tested positive. "[This study] underscores the need for better legislation in this area," said Ellen Matloff of the Yale Cancer Centre where the study took place.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT079876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel